BLAINJECTIONINJECTABLEPriority Review
Approved
Sep 2025
Lifecycle
Launch
Competitive Pressure
30/100
Data completeness
4/8 — Partial
Priority Review
KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph) by Merck & Co. is programmed death receptor-1-directed antibody interactions [moa]. Approved for endoglycosidase [epc]. First approved in 2025.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KEYTRUDA QLEX is a fixed-dose combination of pembrolizumab (a PD-1 checkpoint inhibitor) and berahyaluronidase alfa (a recombinant human hyaluronidase) delivered via subcutaneous injection. It harnesses PD-1 directed antibody interactions to enhance immune response against cancer cells. The hyaluronidase component enables rapid subcutaneous administration by temporarily breaking down hyaluronic acid in the interstitial space.
Launch
New launch in competitive PD-1 space with moderate competitive pressure (30/100); expect scaled commercial infrastructure focused on physician adoption of subcutaneous route.
Mechanism of Action
Programmed Death Receptor-1-directed Antibody Interactions
Pharmacologic Class:
Endoglycosidase
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on KEYTRUDA QLEX positions professionals at the launch phase of a differentiated delivery platform in a high-value oncology indication. Career growth is tied to successful physician adoption of subcutaneous administration and competitive positioning against entrenched PD-1 therapies.
Brand Manager
Worked on KEYTRUDA QLEX at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.